share_log

Tenaya Therapeutics Publishes TN-401 Gene Therapy Preclinical Data In Nature Communications Medicine

Moomoo 24/7 ·  Mar 18 08:34

TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed Disease Progression and Extended Survival in a Severe Mouse Model of Disease

Tenaya Anticipates Dosing First Patient in Phase 1b RIDGE-1 Clinical Trial of TN-401
in Second Half of 2024

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment